Among which, CDX-3379, an anti-ErbB3 monoclonal antibody, has demonstrated antitumor activity resulting in tumor shrinkage in 42% of HNSCC patients, with grade 1 to 2 diarrhea, fatigue, and acneiform dermatitis being the most often treatment-related toxicities75. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.